Novel theranostic nanoagent based on CuMo ₂ S ₃ ‐PEG‐Gd for MRI‐guided photothermal/photodynamic/chemodynamic therapy

Abstract

Abstract Cancer is a severe disease, which have troubled human being for a long time. The development of nanotechnology has provided a new way for cancer treatment. It is a promising strategy to integrate imaging and therapeutic functions into one single nanoplatform to achieve efficient combination of diagnosis and treatment. Herein, we exploited novel CuMo 2 S 3 ‐PEG‐Gd nanocomposites (NCs) for magnetic resonance imaging (MRI), guiding the photothermal therapy (PTT)/photodynamic therapy (PDT)/chemodynamic therapy (CDT). The experimental results showed that CuMo 2 S 3 ‐PEG‐Gd NCs have a high photothermal conversion efficiency (40.6%), excellent biocompatibility and good biosecurity. The CuMo 2 S 3 ‐PEG‐Gd NCs exhibited a clear MRI performance for tumor due to connecting Gd, which can guide in vivo therapy to improve the therapeutic effect. Moreover, both in vitro and in vivo therapeutic results of CuMo 2 S 3 ‐PEG‐Gd NCs exhibited that the PTT/PDT/CDT achieved a remarkably synergistic effect, which could efficiently inhibit the tumor growth. Thus, CuMo 2 S 3 ‐PEG‐Gd NCs, which integrated imaging with multiple therapies, have a good potential as theranostic agent for tumor.